Latest Lucentis Stories
WASHINGTON - What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing.
What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
The National Institute for Health and Clinical Excellence has recommended Novartis's Lucentis as a cost-effective therapy for all eligible patients with wet age-related macular degeneration.
THOUSANDS of people all over the country will be able to receive sightsaving drugs thanks to a campaign spearheaded by three Warwickshire patients. The drug Lucentis will now be available on the NHS to anyone with 'wet' macular degeneration - an eye disease which sends sufferers blind.
By Paul Greaves A war veteran who fought a campaign to get a sight-saving drug on the NHS says he feels "vindicated" it will now be made freely available across the country.
By JULIA BRADSHAW People who face going blind will now have access to a sight- saving drug on the NHS following a massive campaign to make the medication more widely available.
By Mike Waites Health Correspondent The National Institute for Clinical Excellence (Nice) has backed NHS treatment using the drug Lucentis for the devastating eye condition wet age-related macular degeneration (AMD) following a two- and-half-year battle by patients.The Yorkshire Post revealed last month that people affected by the condition in the region are already being treated using the drug but the decision means the national postcode lottery of care will now end.The disease is the...
By Jane Kirby Thousands OF people with a devastating eye disease could have their sight saved by a new drug being made available on the NHS, under guidelines published today.
Three elderly patients have launched a landmark High Court challenge over an NHS trust's "absolutely ridiculous" refusal to fund potentially sight-saving treatment.
WALTHAM, Mass., June 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Genentech/Novartis's Lucentis will become the Decision Resources' proprietary clinical gold standard by 2011 because of its ability to generate higher total sales in the United States and Europe due to its higher price.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.